SingleTimeMicroneedles, a Farmington, CT-based microneedle drug development and delivery company, raised an undisclosed amount in Pre-Seed funding.
The round was led by Health Advance Partners.
The company intends to use the funds to expand operations and development efforts.
Led by CEO Jasdeep Singh, SingleTimeMicroneedles (STM) has developed a drug and vaccine microneedle delivery platform to enable access to pharma products in animals and humans. The microneedle patch temperature stabilizes drugs and vaccines to eliminate the need for cold-chain storage and transportation. The patches can deliver doses immediately, over time, or separately over weeks/months in one application. The technology supports most types of vaccines and therapeutics, including large molecules, subunit protein-based antigens, vector-based vaccines, mRNAs, and any compound that benefits from multiple/longitudinal dosing. STM patches have broad applications and are being planned for use in animals and humans.
Commenting on the news, Jasdeep Singh said: “Investing in an early-stage growing biotech/pharma company requires agreement on the long-term vision and a collaborative spirit, and for those reasons, we at STM are incredibly excited to welcome Health Advance Partners to the team.”
FinSMEs
14/02/2024